Core Viewpoint - Kefu Medical has submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for expanding overseas sales channels, global investments and acquisitions, research and development innovations, and domestic market promotion [1] Group 1: Company Overview - Kefu Medical is a leading enterprise in China's home medical device industry, with over 200 product categories [1] - The company ranks second in sales in China for 2024 [1] - Kefu Medical is actively expanding its online channels, covering all major e-commerce platforms, and is projected to rank second in online sales in the industry for 2024 [1] Group 2: Business Operations - As of June 30, 2025, Kefu Medical operates 738 self-owned stores, with 689 being "Jianer Hearing" service centers, covering 135 cities nationwide [1] - The rehabilitation aids segment is the most significant growth area for revenue, particularly in correction, posture correction products, and hearing aids [1]

Core Viewpoint - Company Kefu Medical is seeking to list on the Hong Kong main board after less than four years on the ChiNext, indicating a strategic move beyond mere secondary financing [1] Group 1: Company Overview - Kefu Medical has been focused on the home medical device industry since its establishment in 2007, providing convenient solutions for consumers and patients seeking high-quality and advanced home medical devices [2] - The company's product portfolio includes over 20 categories, with a significant emphasis on online sales, achieving a total online sales revenue of 1.981 billion in 2024 [2] - Revenue figures for Kefu Medical from 2022 to 2025 (first six months) are as follows: 2.977 billion, 2.854 billion, 2.983 billion, and 1.496 billion respectively, with net profits of 302 million, 253 million, and 3.02 billion [2][4] Group 2: Product Performance - The rehabilitation aids segment has shown the most significant growth, with revenues of 526 million, 718 million, and 1.039 billion from 2022 to 2024, accounting for 17.7%, 25.2%, and 34.8% of total revenue respectively [4] - Kefu Medical operates 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, covering over 135 cities [4] Group 3: Market Dynamics - The global home medical device market is projected to have a combined share of approximately 63.3% from home rehabilitation aids, medical care products, health monitoring products, and respiratory support devices in 2024, expected to rise to 64.1% by 2030 [5] - In China, online sales through platforms like Taobao, JD.com, Douyin, and Xiaohongshu are expected to account for about 44.3% of total market sales in 2024, while offline channels contribute 55.7% [5] Group 4: Strategic Expansion - Kefu Medical is actively expanding into overseas markets through platforms like TikTok Shop, Temu, and Amazon, with overseas business revenue steadily increasing since 2022 [5] - The company aims to use the funds raised from the Hong Kong listing to promote overseas sales channels and establish a distribution network, as well as for potential strategic investments and acquisitions globally [5] - If the Hong Kong listing is successful, Kefu Medical will establish an "A+H" dual capital platform, enhancing its financial strength and brand influence [5]

Core Viewpoint - Company seeks to list on the Hong Kong main board after nearly four years on the ChiNext, indicating a strategic move for further capital raising and global expansion [1][2]. Company Overview - Founded in 2007, the company specializes in home medical devices, offering over 200 product categories and thousands of specifications, ranking second in China's home medical device market by sales in 2024 [3]. - The company has expanded its international presence, operating in over 60 countries and regions across Asia, Africa, Europe, and America, establishing a global user base [3]. Financial Performance - Revenue figures for the company are as follows: 29.77 billion RMB in 2022, 28.54 billion RMB in 2023, 29.83 billion RMB in 2024, and 14.96 billion RMB for the first half of 2025. Net profits were 3.02 billion RMB, 2.53 billion RMB, 3.12 billion RMB, and 1.67 billion RMB for the same periods, indicating stable profitability [3]. - The company’s online sales reached 19.81 billion RMB in 2024, ranking second among Chinese home medical device companies [3]. Product Segmentation - The company’s revenue is primarily derived from three segments: medical health products, custom manufacturing, and other businesses, with medical health products contributing approximately 90% of total revenue [4]. - The rehabilitation aids segment has shown significant growth, with revenues of 5.26 billion RMB in 2022, 7.18 billion RMB in 2023, and 10.39 billion RMB in 2024, accounting for 17.7%, 25.2%, and 34.8% of total revenue respectively [6]. Market Trends - The global home medical device market is projected to maintain a significant share from rehabilitation aids, medical care products, health monitoring, and respiratory support devices, expected to account for 63.3% in 2024 and increase to 64.1% by 2030 [7]. - In China, online sales through platforms like Taobao and JD.com contributed approximately 44.3% of total sales in 2024, while offline channels accounted for 55.7% [8]. Global Expansion Strategy - The company is actively pursuing overseas market opportunities, with international sales revenue increasing from 1.4% in 2022 to 2.0% in 2024, and further rising to 6.5% in the first half of 2025 [8]. - The company plans to use funds from the Hong Kong IPO to enhance overseas sales channels, establish distribution networks, and invest in research and development for innovative products [9].